Study of JS004 Combined With Toripalimab for Advanced Lung Cancer
Status:
Recruiting
Trial end date:
2024-08-30
Target enrollment:
Participant gender:
Summary
This is an open-label phase I/II study to evaluate the safety, tolerability, pharmacokinetics
and initial efficacy of JS004 injection combined with toripalimab in patients with advanced
lung cancer who have failed standard therapy.